hrcak mascot   Srce   HID

Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2016.57.582

Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market

Diana Mance   ORCID icon orcid.org/0000-0001-6746-8693 ; 1Department of Physics, University
Davor Mance   ORCID icon orcid.org/0000-0002-6206-2464 ; Faculty of Economics, University of Rijeka, Rijeka, Croatia
Dinko Vitezić   ORCID icon orcid.org/0000-0002-6295-6580 ; School of Medicine, University of Rijeka, Rijeka, Croatia

Puni tekst: engleski, pdf (412 KB) str. 582-590 preuzimanja: 106* citiraj
APA 6th Edition
Mance, D., Mance, D. i Vitezić, D. (2016). Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market. Croatian medical journal, 57 (6), 582-590. https://doi.org/10.3325/cmj.2016.57.582
MLA 8th Edition
Mance, Diana, et al. "Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market." Croatian medical journal, vol. 57, br. 6, 2016, str. 582-590. https://doi.org/10.3325/cmj.2016.57.582. Citirano 16.09.2019.
Chicago 17th Edition
Mance, Diana, Davor Mance i Dinko Vitezić. "Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market." Croatian medical journal 57, br. 6 (2016): 582-590. https://doi.org/10.3325/cmj.2016.57.582
Harvard
Mance, D., Mance, D., i Vitezić, D. (2016). 'Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market', Croatian medical journal, 57(6), str. 582-590. https://doi.org/10.3325/cmj.2016.57.582
Vancouver
Mance D, Mance D, Vitezić D. Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market. Croat Med J. [Internet]. 2016 [pristupljeno 16.09.2019.];57(6):582-590. https://doi.org/10.3325/cmj.2016.57.582
IEEE
D. Mance, D. Mance i D. Vitezić, "Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market", Croatian medical journal, vol.57, br. 6, str. 582-590, 2016. [Online]. https://doi.org/10.3325/cmj.2016.57.582

Sažetak
Aim To develop a new method of health-economic analysis
based on a marginal approach.
Methods We tested the research hypothesis that a detailed
comparative a priori incremental cost-effectiveness analysis
provides the necessary input for budget impact analysis
about the proper order of introduction of new therapies,
and thus maximizes the cost-effectiveness bounded
by the total budget constraint. For the analysis we chose a
combination therapy for the treatment of hepatitis C virus
(HCV) genotype 1 (GT1) infection, which was approved by
the European Medicine Agency in 2015. We used the incremental
cost-effective approach to assess the increase
in the percentage of patients achieving sustained virological
response (SVR) and the expenditure per additional SVR
modulated by the new therapy’s market entrance dynamics.
Patient subpopulations were differentiated by their response
to previous treatment, presence of cirrhosis, and
HCV GT1 subtype. Final parameters were estimated by
Monte Carlo simulations.
Results The new combination therapy had high efficacy,
shorter duration, and was better tolerated than alternative
interventions. The research hypothesis was confirmed:
gradual introduction of the new therapy on the market,
based on a priori incremental cost-effectiveness analysis,
would result in average increase in successfully treated patients
by 20%-40%, while additional costs would approximately
be between 8%-40%, ie, €21 000-52 000 per additional
patient achieving SVR.
Conclusion We showed the new combination therapy
to be cost-effective for certain patient subpopulations,
especially for experienced cirrhotic HCV GT1 patients. Results
of the analysis are in agreement with the latest recommendations
for HCV patients’ treatment in Croatia. This
economic evaluation could serve as a starting point for
negotiations between pharmaceutical industry and insurance
companies.

Hrčak ID: 181398

URI
https://hrcak.srce.hr/181398

Posjeta: 171 *